realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Incyte Corporation
- Study ID
- NCT04981795
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Tafasitamab — DRUGObservational Study on safety and effectiveness of tafasitamab in combination with lenalidomide inPatients With Relapsed or Refractory DLBCL.
Study Details
The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.
Key Dates
- Start date
- Sep 20, 2021
- Status verified
- Apr 2026
- Primary completion
- Jan 23, 2026
- Completion
- Jan 23, 2026
Study Design
- Enrollment
- 102 participants (actual)
Arms
- Arm: 1Group 1: Racial and ethnic minority patients (at least 50 patients)
- Arm: 2Group 2: Non Hispanic White (NHM) patients (at least 50 patients)
Primary Outcome Measure
Treatment Patterns - Safety [ Time Frame: 2 Years ]
Locations (26)
Find similar trials in Birmingham, AL
Related Studies
- A Long-term Extension Study of PCI-32765 (Ibrutinib)PHASE3 · Recruiting · Janssen Research & Development, LLC · Duarte, California
- Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHLPHASE2 · Recruiting · New York Medical College · Valhalla, New York
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaPHASE1/PHASE2 · Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaPHASE2 · Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland